Breast Cancer Excellence Forum

Breast Cancer

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer

11/30/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; and Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...

Cynthia Ma, MD, leads part 1 of...

11/30/2023

Oncology

Sherene Loi, MBBS, PhD, Peter MacCallum Cancer Center

Videos

Adding Nivolumab to Neoadjuvant Chemotherapy Improved Response Rate Among Patients With High Risk, ER Positive, HER2 Negative Breast Cancer

10/21/2023

Featuring Sherene Loi, MBBS, PhD

Featuring Sherene Loi, MBBS, PhD ...

At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.

At the 2023 ESMO Annual...

10/21/2023

Oncology

Sara Tolaney, MD, MPH, Dana-Farber Cancer Institute

Videos

Sacituzumab Govetican Improves Survival Outcomes For Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/08/2023

Sara Tolaney shares the final overall survival analysis of the phase 3 TROPiCS-02 trial, evaluating sacituzumab govitecan in pretreated metastatic HR-positive breast cancer, which was presented at the 2023 ASCO Annual Meeting

Sara Tolaney shares the final...

06/08/2023

Oncology

Erika Hamilton, MD, Sarah Cannon Research Institute

Videos

HER3-DXd for Metastatic Breast Cancer Across Subtypes

06/05/2023

At the 2023 ASCO Annual Meeting, Erika Hamilton, MD, discusses the antibody drug conjugate HER3-DXd, or patritumab deruxtecan.

At the 2023 ASCO Annual Meeting,...

06/05/2023

Oncology

Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA

Videos

Genomic Differences Among HER2-Low, HER2-Zero, and HER2-Positive Breast Cancer

04/28/2023

Paolo Tarantino, MD, discusses advancements in genomic study and treatment efficacy for HER2-Low, HER2-Zero, and HER2-Positive breast cancers.

Paolo Tarantino, MD, discusses...

04/28/2023

Oncology

Mylin Torres, MD, Winship Cancer Institute

Videos

Five-Fraction Radiation Regimens for Early-Stage Breast Cancer

03/20/2023

At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.

At the 2023 ACRO Radiation...

03/20/2023

Oncology

Hyman Muss, MD, Linberger Cancer Center at the University of North Carolina, Chapel Hill, NC

Videos

Management of Older Patients With Breast Cancer

03/17/2023

Hyman Muss, MD, outlines the important considerations for providers caring for older patients with breast cancer.

Hyman Muss, MD, outlines the...

03/17/2023

Oncology

Hyman Muss, MD, Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Videos

Delivering Effective End-of-Life Care for Patients With Breast Cancer

03/17/2023

Hyman Muss, MD, details his best practices for delivering effective end-of-life care for patients with breast cancer.

Hyman Muss, MD, details his best...

03/17/2023

Oncology

Kelly Hunt, MD, MD Anderson Cancer Center, Houston, TX

Videos

Axillary Reverse Mapping: Preventing Lymphedema Among Patients With Breast Cancer

03/16/2023

Kelly Hunt, MD, discusses the practice of axillary reverse mapping in the prevention of lymphedema for patients with breast cancer.

Kelly Hunt, MD, discusses the...

03/16/2023

Oncology

Videos

Metronomic Chemotherapy for Patients With Breast Cancer

03/16/2023

Dr Hyman Muss offers his insights on how metronomic chemotherapy can fit into the treatment paradigm for patients with breast cancer.

Dr Hyman Muss offers his...

03/16/2023

Oncology

Recent News

News

National Analysis Provides Greater Insights in HER2-Low Metastatic Breast Cancer

09/29/2021

Findings from a national retrospective analysis of patients with HER2-low metastatic breast cancer were presented at the virtual 2021 ESMO Congress to exhibit distinct clinical outcomes.

Findings from a national...

09/29/2021

Oncology

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology